R E C I T A L SLetter Agreement • June 6th, 2005 • Nutra Pharma Corp • Medicinal chemicals & botanical products • California
INTRODUCTIONSecurities Purchase Agreement • August 23rd, 2005 • Nutra Pharma Corp • Medicinal chemicals & botanical products • California
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 12th, 2010 • Nutra Pharma Corp • Medicinal chemicals & botanical products • Illinois
REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of November 8, 2010, by and between NUTRA PHARMA CORP., a California corporation, (the "Company"), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with it permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the "Purchase Agreement").
PURCHASE AGREEMENTPurchase Agreement • November 12th, 2010 • Nutra Pharma Corp • Medicinal chemicals & botanical products • Illinois
PURCHASE AGREEMENT (the “Agreement”), dated as of November 8, 2010, by and between NUTRA PHARMA CORP., a California corporation, (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”).
XENACARELetter of Intent • December 21st, 2004 • Nutra Pharma Corp • Medicinal chemicals & botanical products
AGREEMENT AND PLAN OF MERGERMerger Agreement • April 14th, 2008 • Nutra Pharma Corp • Medicinal chemicals & botanical products • Florida
This Agreement and Plan of Merger, dated as of this 9th day of April, 2008 (the “Agreement”), by and among Nutra Pharma Corp., a California corporation (“Nutra Pharma”), NP Acquisition Corporation, a Nevada corporation wholly owned by Nutra Pharma (“Acquisition”), Receptopharm, Inc., a Nevada corporation (“Receptopharm”) and the stockholders of Receptopharm listed on the signature pages hereto (collectively, the “Executing Stockholders,” and together with Nutra Pharma and Receptopharm shall be referred to collectively as, the “Parties”). Terms used herein and not otherwise defined shall have the meaning set forth in Article IX hereof.
Xinhua Financial Network Ltd. 2003-5 Vicwood Plaza 199 Des Voeux Road Central Hong KongConsulting Agreement • November 10th, 2005 • Nutra Pharma Corp • Medicinal chemicals & botanical products • New York
Reference is made to the Agreement, dated September 30, 2005, between Xinhua Financial Network Ltd. (“XFN”) and Nutra Pharma Corp. (the “Company”).
Termination AgreementTermination Agreement • April 7th, 2006 • Nutra Pharma Corp • Medicinal chemicals & botanical products • Florida
This Agreement is made by and between Nutra Pharma Corp., a California Corporation (“the Company”), with an address of 3473 High Ridge Road, Boynton Beach, FL 33426 (“the Company”), and Doherty & Company, LLC, a Delaware limited liability company (“Doherty & Company”) and Michael Doherty, an individual (“Doherty”). Doherty & Company, LLC and Doherty are referred to herein individually or collectively as “the Doherty Entities.”
ACQUISITION AGREEMENTAcquisition Agreement • January 7th, 2005 • Nutra Pharma Corp • Medicinal chemicals & botanical products • Florida
THIS AGREEMENT (hereinafter “the agreement”), made and entered into as of the 28th day of February, 2004 and modified on the 31st day of December, 2004, by and between Nutra Pharma Corp., a California corporation (hereinafter “Nutra Pharma”), and Receptopharm, Inc., a Nevada corporation (hereinafter “Receptopharm”), by and for the benefit of its shareholders, who, in consideration of the mutual promises and covenants contained herein, agree as follows:
Exhibit 10.12 Nutra Pharma Corp. INVESTOR-GATE.COM(R) 18533 Roscoe Blvd #207, Northridge CA 91324 (818) 679-7444 October 8, 2004 Nutra Pharma Corporation Rik J.Deitsch - CEO Dear Mr. Deitsch: This letter agreement (the "Agreement") confirms the terms...Investor Relations Agreement • December 21st, 2004 • Nutra Pharma Corp • Medicinal chemicals & botanical products • California
PATENT ASSIGNMENT AGREEMENT between NANOLOGIX, INC. and NUTRA PHARMA CORP. Dated ____________, 2006Patent Assignment Agreement • April 17th, 2007 • Nutra Pharma Corp • Medicinal chemicals & botanical products • Pennsylvania
This Patent Assignment Agreement (“Agreement”) is dated ____________, 2006 (“Commencement Date”), by and between NanoLogix, Inc., a Delaware corporation having a place of business at 87 Stambaugh Avenue, Suite 2, Sharon, Pennsylvania 16146 (“Assignor”) and Nutra Pharma Corp., a California corporation having a place of business at 3473 High Ridge Road, Boynton Beach, Florida 33426 (“Assignee”) (each, a “Party” and together, the “Parties”).
LICENSE AGREEMENTLicense Agreement • April 20th, 2004 • Nutra Pharma Corp • Medicinal chemicals & botanical products • Florida
This agreement is made and entered into on the 3rd day of October, 2003, by and between Biotherapeutics, Inc., a Florida corporation having a principal place of business at 1850 NW 69th Avenue, Suite One, Plantation, FL, hereinafter referred to as LICENSOR and Nutra Pharma Corp., a California corporation having a principal place of business at 485 Martin Lane, Beverly Hills, CA, hereinafter referred to as LICENSEE.
Exhibit 10.9 SETTLEMENT AGREEMENT AGREEMENT made this 28th day of September, 2004, by and between NUTRA PHARMA CORP., a California corporation ("Nutra Pharma"), and OPUS INTERNATIONAL, LLC., a Maryland limited liability company ("Opus"), provides as...Settlement Agreement • December 21st, 2004 • Nutra Pharma Corp • Medicinal chemicals & botanical products • California
Exhibit 10.11 Nutra Pharma Corp. AGREEMENT FOR RESEARCH SERVICES THIS AGREEMENT is by and among Nutra Pharma Corp., a California corporation with principal executive offices located at 4001 NW 73rd Way, Coral Springs, Florida 33065 ("Nutra Pharma")...Research Services Agreement • December 21st, 2004 • Nutra Pharma Corp • Medicinal chemicals & botanical products • North Carolina
NUTRA PHARMA CORP. 1829 Corporate Drive, Boynton Beach, FL 33426 Office (954) 509-0911 Fax (866) 744-3655 February 14, 2005 Dr. Tan Khandaker 387 Park Avenue South Third floor New York, NY 10016 Dear Dr. Khandaker: Please allow this letter to serve as...Consulting Agreement • May 2nd, 2005 • Nutra Pharma Corp • Medicinal chemicals & botanical products
AMENDMENT TO LICENSE AGREEMENTLicense Agreement • April 20th, 2004 • Nutra Pharma Corp • Medicinal chemicals & botanical products
This amendment is made and entered into on the 11th day of November, 2003, by and between Biotherapeutics, Inc., a Florida corporation having a principal place of business at 1350 NW 69th Avenue, Suite One, Plantation, FL, hereinafter referred to as LICENSOR and Nutra Pharma Corp., a California corporation having a principal place of business at 485 Martin Lane, Beverly Hills, CA, hereinafter referred to as LICENSEE.
INTERNATIONAL LICENSE AGREEMENTInternational License Agreement • April 17th, 2007 • Nutra Pharma Corp • Medicinal chemicals & botanical products • Pennsylvania
THIS INTERNATIONAL LICENSE AGREEMENT (“Agreement”) is made as of this day of ______, 2006, ("Effective Date") by and between NanoLogix, Inc., a Delaware corporation having a place of business at 87 Stambaugh Avenue, Suite 2, Sharon, Pennsylvania 16146 (“Licensor”), and Nutra Pharma Corp., a California corporation having a place of business at 3473 High Ridge Road, Boynton Beach, Florida 33426 (“Licensee”) (each, a “Party” and together, the “Parties”).
June 1, 2005Indemnification Agreement • June 6th, 2005 • Nutra Pharma Corp • Medicinal chemicals & botanical products • California
In connection with our engagement to advise and assist you with the matters set forth in the engagement letter of even date herewith, you and we are entering into this letter agreement. It is understood and agreed that in the event that Doherty & Company LLC ("Doherty") or any of our members, employees, agents, affiliates or controlling persons, if any (each of the foregoing, including Doherty, being an "Indemnified Person") become involved in any capacity in any action, claim, proceeding or investigation brought or threatened by or against any person, including your stockholders, related to, arising out of or in connection with our engagement, you will promptly reimburse each such Indemnified Person for its legal and other expenses (including the cost of any investigation and preparation) as and when they are incurred in connection therewith. You will indemnify and hold harmless each Indemnified Person from and against any losses, claims, damages, liabilities or expense to which any I
